Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• CTO Abhimanyu Verma sold 5,000 SOPHiA GENETICS shares at an average of $8.20, generating $41,000; the transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced his holdings by 2.74% to 177,171 shares.
• Verma has made several additional sales since June, totaling more than 32,000 shares, while SOPH shares recently traded at $8.53—near the one-year high of $8.85 and up substantially from its $3.10 low.
• The company missed quarterly EPS expectations despite beating revenue estimates. Analysts have a consensus “Hold” rating and a $10 average price target, with institutional investors owning 31.59% of the stock.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CTO Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.20, for a total transaction of $41,000.00. Following the completion of the sale, the chief technology officer owned 177,171 shares of the company's stock, valued at approximately $1,452,802.20. This trade represents a 2.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.80, for a total transaction of $44,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.60, for a total transaction of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total transaction of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Down 1.4%

Shares of SOPH stock traded down $0.12 during trading hours on Wednesday, hitting $8.53. 232,020 shares of the company were exchanged, compared to its average volume of 241,759. The stock has a market capitalization of $715.58 million, a price-to-earnings ratio of -7.42 and a beta of 0.96. SOPHiA GENETICS SA has a one year low of $3.10 and a one year high of $8.85. The business's 50-day simple moving average is $6.33 and its two-hundred day simple moving average is $5.37. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. Sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS during the 4th quarter worth $49,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS during the third quarter valued at $49,000. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS during the first quarter valued at $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter worth about $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter worth about $55,000. Institutional investors and hedge funds own 31.59% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SOPH shares. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. BTIG Research increased their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Finally, HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source